Active, not recruitingPhase 3NCT06384573

DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease

Studying NON RARE IN EUROPE: Alzheimer disease

Last synced from ClinicalTrials.gov May 4, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Washington University School of Medicine
Principal Investigator: Randall J Bateman, MD
Washington University School of Medicine
Intervention: lecanemab(drug)
Enrollment: 40 enrolled
Eligibility: 18 years · All sexes
Timeline: 2024 – 2030

Study locations (6)

University of Alabama in Birmingham, Birmingham, Alabama, United States
Indiana University School of Medicine, Indianapolis, Indiana, United States
Washington University in St. Louis, St Louis, Missouri, United States
University of Washington, Seattle, Washington, United States
Neuroscience Research Australia, Randwick, New South Wales, Australia
The National Hospital for Neurology and Neurosurgery, London, Greater London, United Kingdom

Collaborators

Alzheimer's Association · Eisai Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06384573 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Alzheimer disease

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Alzheimer disease →

← Back to all trials